Is to use the concept of molecular mimicry to physiologically bind well-described pharmacological targets with bacterial metabolites and derived small molecules
TargEDys® translates its unique understanding of the gut-brain axis to develop and manufacture nutritional and therapeutic solutions to control metabolic diseases. The company aims to be at the forefront of safe and effective weight management to improve the health and life quality of many over and underweight people.
The TargEDys research team at the INSERM lab of Rouen University has identified a novel mechanism of appetite regulation involving bacterial, hormonal mimetic, proteins that are found naturally in the gut microbiome. This mechanism acts as the basis of TargEDys’ two technologies: ProbioSatys™ and ProbioNutrys™, which respectively moderate the appetite of overweight people and restore the appetite of elderly, cachexic or anorexic people.
Latest company news and where to find us
TargEDys is in the list of 20 European biotechs to follow in 2020. This list was published by the platform Labiotech.eu which had asked experts to identify the 20 European companies across all areas of biotech that will be hitting key milestones and making headlines in 2020.Read more
Both studies were looking at preclinical validation of Hafnia alvei HA4597 as potential probiotic for appetite and body weight management on overweight and obesity. First study was published in International Journal of Obesity (https://doi.org/10.1038/s41366-019-0515-9), the second in Microorganisms (https://doi.org/10.3390/microorganisms8010035)Read more
EnteroSatys® was named "Best Nutraceutical Product of the Year" at Food Matters Live Awards 2019. The awards ceremony took place on Tuesday 19 November at ExCeL London as a part of a broader event, now in its sixth year, creating cross-sector connections and focusing on the future of food and sustainable nutrition.Read more
The human microbiome is the genome of our microbes. It is 150 times more diverse than our human genome and formed of 5000-different species of bacteria living all over our bodies, especially our gut, mouth and skin. This symbiotic bacterial community is vital for day-to-day bodily functions such as immunity, defence against pathogens, host nutrition, synthesis of vitamins, fat storage and influencing human behaviour. An imbalance in one’s microbiome has been linked to a range of diseases such as Diabetes, Cancer and Obesity. A key step to unlocking the potential of many microbiome based treatments is to fully understand the microbiome and its interactions with the human host.
The gut-brain axis is the bidirectional communication between the central and enteric nervous systems, linking the emotional and cognitive centres of the brain with peripheral intestinal functions. Gut microbiota are very important in influencing these interactions. TargEDys® has discovered a new mechanism of appetite regulation that involves this axis and has developed two types of innovative technology for the treatment of over and underweight patients, ProbioSatys™ and ProbioNutrys™ respectively.
After a meal, intestinal bacteria feed on the ingested food and begin to multiply. During this growth phase, the bacteria produce various signals that allow them to interact with the brain. One such signal is the protein ClpB, produced by Enterobacteria naturally present in the intestines. ClpB has been identified as a mimetic of the satiety hormone (α-MSH) that regulates food behaviour at both peripheral and central levels.
When released, ClpB directly stimulates the enteroendocrine L-cells of the intestine to produce satiety hormones. ClpB also enters the bloodstream to act on satiety regulation in the central nervous system by mimicking α-MSH. The resulting effect is the feeling of satiety or fullness after a meal.
The basis of the ProbioSatys™ technology is an Enterobacteria probiotic strain that produces satiety protein, ClpB.
• Decrease of body weight gain
• Decrease of food intake
• Improvement of body composition
• Activation of lipolysis
• Activation of central satiety pathways
Hafnia alvei 4597, the probiotic strain used in ProbioSatys®, is a commensal bacterium from the Enterobacteriaceae family, naturally present in the human gut. Hafnia alvei 4597 expresses a protein of interest in the regulation of hunger called caseinolytic peptidase B protein homologue (ClpB). It can also be found in a wide range of traditional foods.
Hafnia alvei was first identified in 1954 in raw milk, and has since been found in traditional cheeses with strong flavours such as Camembert and Livarot. Dairy product contamination during the 1990s led the industrialists to pasteurise their milk, which meant losing the typical aromas appreciated by cheese lovers. Hafnia alvei is now added to pasteurized cheese as a lactic ferment to restore its original flavour.
Hafnia alvei adheres to the intestinal mucosa and resists fasting digestion. It is multiple, and is metabolically active in the colon. Its genome has been fully sequenced and it does not have a plasmid with antibiotic resistance genes. The manufacturing process of Hafnia alvei has been specifically developed for TargEDys.
TargEDys is currently demonstrating the efficacy of another hormone mimetic technology that exploits the gut-brain axis to improve the appetite of anorexic, cachexic or elderly patients.
EnteroSatys® contains Hafnia alvei 4597 strain, zinc and chromium which contribute to a healthy metabolic equilibrium*. Hafnia alvei 4597 is a lactic ferment strain, originally isolated from raw milk cheese. The strain has been studied for many years at the National French Medical & Health Research Institute (INSERM) labs in Normandy.
*Zinc contributes to normal lipid and macronutrient metabolism. Chromium contributes to normal blood glucose levels.
To ensure efficacy of the product, EnteroSatys® is manufactured in DRCAPS™ gastro-resistant capsules.
Role of the Gut Microbiota in Host Appetite Control:
Bacterial Growth to Animal Feeding Behaviour
The life of all animals is dominated by alternating feelings of hunger and satiety — the main involuntary motivations for feeding-related behaviour. Gut bacteria depend fully on their host for providing the nutrients necessary for their growth. […] This Review analyses the data relevant to possible involvement of the gut bacteria in the regulation of host appetite and proposes an integrative homeostatic model of appetite control that includes energy needs of both the host and its gut bacteria.Read more
« Commensal Hafnia alvei strain reduces food intake and fat mass in obese mice—a new potential probiotic for appetite and body weight management ».Read more
« Hafnia alvei HA4597 Strain Reduces Food Intake and Body Weight Gain and Improves Body Composition, Glucose, and Lipid Metabolism in a Mouse Model of Hyperphagic Obesity ».Read more
« Prevalence of eating disorders over the 2000–2018 period: a systematic literature review ».Read more
6th February 2020
TargEDys® announces the successful completion of its 3 months, randomized, double blind, placebo-controlled, multicentric clinical study carried out on 229 subjects and evaluating the efficacy of Hafnia alvei HA4597 TM in the weight loss by regulation of the appetite.Read more
9th October 2019
The French startup TargEDys presents the first natural approach to regulate appetiteRead more
15th July, 2019
TargEDys announces that BIOCODEX has acquired a share of its capital and appoints new board members.Read more
January 31, 2019
EnteroSatys® is the first probiotic specifically designed to control appetite. It is composed of Hafnia alvei 4597, supplemented with chromium and zinc and is based on patented molecular mimicry technology. A protein produced by H.alvei imitates α-MSH, a hormone that signals satiety.Read more
15th November 2018
Neovia signs an R&D partnership with TargEDys and continues to innovate on the petcare marketRead more
2nd July, 2018
Philippe Lavielle appointed Chairman of the TargEDys Board of DirectorsRead more
04th April 2017
TargEDys extends Series A and appoints new Board Members.Read more
9th March 2017
Bpifrance soutient TargEDys et lui octroie une aide pour le développement à l’innovation de 1,1 million d’euros.Read more
18th July 2016
TargEDys, laureate of the International Innovation Contest (CMI)Read more
TargEDys has completed Series A funding of 10.6 M€ and will begin Series B in 2020.
NCI is an investment company operating in Normandy and in Ile de France. NCI strives to create sustainable value within its portfolio companies by reconciling finance, economic development and social welfare.For more details
Pontifax is a venture capital firm focusing on groundbreaking innovations in the life sciences arena. Founded in 2004 and with $350M under management, Pontifax seeks transformative, innovative healthcare opportunities at all development stages.For more details
With over €660m in assets under management, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure Partners has invested in innovative businesses with high growth potential in two fields: Digital technologies and Life sciences.For more details
Biocodex is an independent multinational pharmaceutical company built on high-standard science and manufacturing, with six decades of proven success. Founded in 1953, the company’s initial focus was gastroenterology featuring a unique probiotic Saccharomyces boulardii CNCM I-745®, the first probiotic drug of its kind that has a positive effect on the gut’s microflora.For more details
The main strengths of the team are a very strong Board and Development Committee and CEO with valuable experience running biotech companies, marketing, research and launch products both medical and nutraceutical.
Grégory LAMBERT's career has been split between biotech and pharmaceutical companies, in roles such as VP of R&D and General Manager of Novagali Pharma (now Santen) and CSO at Septodont. His responsibilities covered management of IP and business development activities, innovation and CMC as well as pre-clinical and clinical development in Europe and North America. Gregory is an inventor on more than 20 patents, he was involved in the IPO of Novagali Pharma and he drove the development of several pharmaceutical products from the laboratory to market authorisations. In 2014, Gregory joined the scientific founders of TargEDys as CEO to setup the business plan and start operations.
Philippe LAVIELLE is an accomplished entrepreneur. He is currently Chairman and CEO of Fermentalg, a French industrial biotech company specialising in microalgae derived products. Until July 2014 Philippe was President and CEO of Virdia Inc., a biotech company producing carbohydrates from cellulosic biomass. His teams developed one of the world’s most advanced ligno-cellulosic bio-refinery platforms. Prior to joining Virdia, Philippe was Executive Vice President of Genencor Inc., the US based world leader in industrial biotechnology in renewable fuels and bio-chemicals. Philippe is also a Board member of Clara Foods Inc., a US company working towards creating the world’s first animal-free egg white.
Danilo has extensive experience as a senior pharmaceutical executive and as a highly successful serial entrepreneur. Most recently he was a founder and President of CM&D Pharma Ltd, a medical foods company he founded in 2007 and sold to Nestle Health Science in 2011. He is currently a Director on the boards of companies based in the USA, Italy, Ireland, Finland and France as well as a Cofounder in some of them. Danilo is an expert in start-ups and co-ventures in the pharmaceutical sector.
Isabelle is President and CEO of Seventure Partners and manages the Life Sciences team. She brings 25 years of international experience in life sciences business development and finance. Isabelle leads the life sciences team and makes direct investments, mainly in France and Scandinavia and in the US/Canada with a focus on biotech, nutrition, personalised medicine and especially microbiome. Isabelle’s track record includes Santaris (sold to Roche for $450 millions in august 2014), Argenx (listed), OPI pharma (sold to Eusa for Euro 110 millions), Bioalliance (listed), Pixium Vision (listed), as well as Enterome Bioscience, Maat Pharma and TargEDys.
Eric is Venture Partner with Seventure Partners, a Paris-based venture investor investing broadly in life sciences, with a specific focus on the human microbiome. Seventure closed the first microbiome fund worldwide, called Health for Life, in December 2015. Formerly, Eric was the CEO of a Swiss Biotech company and has led Roche’s global function of External Research and Technologies. Eric is a scientist by training (protein structure determination by X-ray crystallography). He was trained as an engineer and physicist at Ecole Centrale de Paris, holds a Ph.D. in Biophysics from Paris XI University, and an MBA (honors) from INSEAD.
Jean-Marie is President and CEO of Biocodex. He steered the creation of the “Biocodex Microbiota Institute” supporting innovative projects from Microbiota researchers. Jean-Marie has a long-track record of CEO positions amongst international firms such as LVMH or Bongrain. Engineering from Ecole Centrale Paris, MBA from Insead
Virginie Husson has long-track record of experience in various financial functions, including the current one as VP Finance at Biocodex. She was responsible for managing the Biocodex Group consolidation and previously she has led to success several projects in international companies like GreatBatch Medical or Sidel.
Laurie is an investment analyst at NCI, a Normandy -based structure which invests in companies operating in Normandy and in Paris. NCI accompanied more than 130 firms at different stages (VC, LBO, growth capital) and in diverse industries. With a double-digit growth track record, and €180M in managed assets (entrusted by public and private institutional investors), NCI conciliates finance and economic development. Laurie graduated from Rouen Business School in Corporate Finance and passed all the three levels of the CFA Program.
Eric has extensive international commercial experience in Pharma (orphan and specialty drugs, health care products and services) and Nutrition (especially microbiome).Eric holds a Ph.D in Pharmacy and assumed senior leadership roles with proven-track record amongst international firms such as Actelion, Sanofi and Danone. In particular at Actelion, he built and grew the commercial teams across Europe, Russia/CIS and LatAm, then successfully handled the full integration of Actelion into Janssen. Currently he undertakes consulting assignments and manages board member positions. His passion: Support SME in Pharma/Biotech/Nutrition and create value for patients with unmet medical needs across the world.
Zone d'activités Nativelle
1 Chemin de Saulxier
Tel: +33 1 72 48 84 57
Faculté de Médecine et de Pharmacie
Bâtiment Recherche - 4ème étage
22 boulevard Gambetta
Download detailed access plan including car and public transportation Access Plan TargEDys.pdf
Document Adobe Acrobat [198.6 KB]